Hematological Cancers Market Review with Comparative Analysis
Rapidly increasing hematological cancer prevalence among the population pool, large investment by key market players, and a number of premium drugs commercially available are the factors driving the global hematological cancers market. According to the National Cancer Institute, globally, hematological cancer is the fifth most commonly occurring cancer and it is the second major cause of death in the U.S. Rich pipeline of products for leukemia is also likely to propel the market post commercialization. Increasing incidence of hematological cancers is expected to boost the global market in the next few years. However, low prevalence rate of myeloma is expected to hamper the growth of the global hematological cancers market during the forecast period.
Obtain Report Details: http://www.transparencymarketresearch.com/hematological-cancers-market.html
The hematological cancers market has been segmented based on treatment, disease indication, and region. In terms of treatment, the hematological cancers market has been categorized into stem cell transplantation, pharmacological therapies, radiation, and surgery therapy. In terms of disease indication, the market has been segmented into leukemia, lymphoma, and myeloma. Prevalence of leukemia is higher than that of lymphoma and myeloma. Moreover, a number of blockbuster, biologically effective drugs are available for the treatment of leukemia. Hence, end-users prefer biological, blockbuster products as compared to chemotherapy drugs.
Geographically, the global hematological cancers market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a significant share of the global hematological cancers market owing to extensive research and development activities in the region. Improvement in reimbursement scenario and rich product pipeline are likely to drive the market in North America through 2024. Moreover, rising trend of patent protection is expected to boost the hematological cancers market in the next few years. Europe is expected to be the second largest market for hematological cancer treatment in terms of revenue due to enhanced product availability and implementation of cancer treatment alternatives in the region. Favorable reimbursement policies and regulatory framework highly focusing on cancer patient safety are expected to fuel the hematological cancers market in Europe from 2016 to 2024. High awareness about cancer treatment and increasing new product launches for substitute treatment options are the major factors driving the market in Asia Pacific. Investments by leading pharmaceutical players to develop new drugs is expected to boost the growth of the hematological cancers market in developing countries such as China and India. Countries in Latin America such as Mexico and Brazil are expected to have considerable potential in the hematological cancers market due to increasing cancer treatments and rising health care expenditure.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18482
Major players operating in this market include Novartis International AG, Celgene Corporation, AbbVie, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hematological Cancers Market Review with Comparative Analysis here
News-ID: 556641 • Views: 176
More Releases from TMR - Research Reports
Visualization and 3D Rendering Software Market: On-Premise Deployment Presently …
The global market for visualization and 3D rendering features a largely consolidated vendor landscape, with the leading three vendors accounting for a nearly 80% of the overall revenue generated in the market in 2016, observes Transparency Market Research in a recent report. These three vendors, namely Autodesk Inc., Dassault Systems, and NVIDIA Corporation, have strengthened their positions in the market with the help of cost competitive pricing, continuous introduction of
Digital Door Lock Systems Market: Enhanced Security Requirements to Propel the D …
According to a new market report published by Transparency Market Research titled “Digital Door Lock Systems Market–Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026,” the global digital door lock systems market was valued at US$ 1,059.5 Mn in 2017 and is expected to expand at a CAGR of 30.25% from 2018 to 2026, reaching US$ 14,877.6 Mn by the end of the forecast period. digital door lock systems market
Transportation Management System Market: Advance Technologies in All the Sectors …
A transportation management system (TMS) refers to a subset of supply chain management and is centered mostly on logistics and transportation. The augmented use of cloud computing technologies for managing supply chain activities is one of the significant and major trends that have been prevailing in the world market for transportation management systems. Cloud-based deployments, in general, need less configuration and customization. These two factors are triggering down the cost
Energy Recovery Ventilators Market: Rising Awareness of Importance of Indoor Air …
Characterized by the presence of a handful of dominant players, namely United Technologies Corp., LG Electronics, Daikin Industries Ltd., Fujitsu Ltd., and Munters Corp., the global energy recovery ventilators market features intense competition, reveals Transparency Market Research (TMR) in a new report. Going forward, the rising number of players seeking entry will further intensify competition in the market. Expansion of product portfolio which has been the focus of established companies to
More Releases for Hematological
Advanced Technologies Of Hematological Disorders Market 2017
Albany, NY, 23rd November : Recent research and the current scenario as well as future market potential of "Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need" globally. The hematological disorders therapy area encompasses non-malignant disorders of the blood such as anemia, sickle cell disease, neutropenia and hemophilia. Get PDF for
Hematological Disorders - Pipeline Insight and Therapeutic Assessment Reviewed i …
Market Research Hub (MRH) has recently added a new report on “hematological disorders therapy” area encompasses non-malignant disorders of the blood such as anemia, sickle cell disease, neutropenia and hemophilia. These diseases can be grouped into the three categories- red blood cell disorders, bleeding disorders and immune cell disorders - of which red blood cell disorders are characterized by significant unmet need related to few effective treatment options and poor
Hematological Cancers Market 2017 Trends and Review
The Global Hematological Cancers Market Research Report 2017 to 2022 renders deep perception of the key regional market status of the Hematological Cancers Industry on a global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan. Request for sample of Hematological Cancers Market research report @ https://goo.gl/BeUKBz Split by product type,
Hematological Malignancies Market Is Expected To Profits
Global Hematological Malignancies Market: Snapshot Hematological malignancies, commonly known as hematological cancer, is registering a widespread prevalence across the world. According to the National Cancer Institute, hematological cancer is the fifth most commonly occurring cancer, globally, and is the second prominent reason behind the cancer death in the U.S. Researchers expect the incidence of hematological malignancies to increase further in the coming years, which will result in the growing need for
Hematological Malignancies Market grows with growing prevalence of hematological …
The global hematological malignancies market is highly competitive in nature and is characterized by a consolidated nature, owing to the presence of a few players holding a large share of the overall market, states a research study by Transparency Market Research. The leading players operating in the global market, including Roche, Celgene, Novartis, and AbbVie are anticipated to remain dominant throughout the forecast period. In order to maintain their position
Rapidly Increasing Hematological Cancer Prevalence among the Population Drives t …
Hematological cancer, commonly known as hematological malignancy, is a class of cancer that affects the lymph nodes, blood, and bone marrow. It includes numerous forms such as lymphoma, leukemia, and myeloma. Leukemia is a malignancy in which abnormal white blood cells are formed in the bone marrow. Lymphoma is a blood cancer that develops in the lymphatic system. Myeloma is a cancer associated with the plasma of the white blood